TPX-0131 is a next-generation ALK inhibitor drug candidate currently being evaluated in our Phase 1/2 FORGE-1 clinical trial of patients with ALK+ advanced non-small lung cancer (NSCLC). It has been designed with a novel compact macrocyclic structure and has shown preclinical potent inhibition of wildtype and numerous ALK mutations, including the clinically observed G1202R solvent-front mutation and the G1202R/L1196M compound mutation.
武汉永璨生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
武汉永璨生物